CN101522676A - 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 - Google Patents

用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 Download PDF

Info

Publication number
CN101522676A
CN101522676A CNA2007800367748A CN200780036774A CN101522676A CN 101522676 A CN101522676 A CN 101522676A CN A2007800367748 A CNA2007800367748 A CN A2007800367748A CN 200780036774 A CN200780036774 A CN 200780036774A CN 101522676 A CN101522676 A CN 101522676A
Authority
CN
China
Prior art keywords
amino
methyl
oxo
ethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800367748A
Other languages
English (en)
Chinese (zh)
Inventor
杰夫·扎布沃茨基
奥德蕾·格卢什科夫
铁木尔·西尔伯施泰因
埃里克·帕克希尔
德米特里·科尔通
纳塔利娅·瓦西列维奇
杰弗里·奇泽姆
阿列克谢·伊万诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN101522676A publication Critical patent/CN101522676A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
CNA2007800367748A 2006-10-05 2007-10-05 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物 Pending CN101522676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84964806P 2006-10-05 2006-10-05
US60/849,648 2006-10-05

Publications (1)

Publication Number Publication Date
CN101522676A true CN101522676A (zh) 2009-09-02

Family

ID=39106151

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800367748A Pending CN101522676A (zh) 2006-10-05 2007-10-05 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物

Country Status (12)

Country Link
US (2) US7732453B2 (enExample)
EP (1) EP2066665A2 (enExample)
JP (1) JP2010505881A (enExample)
KR (1) KR20090057416A (enExample)
CN (1) CN101522676A (enExample)
AU (1) AU2007303056A1 (enExample)
BR (1) BRPI0717502A2 (enExample)
CA (1) CA2665476A1 (enExample)
IL (1) IL197828A0 (enExample)
MX (1) MX2009003658A (enExample)
RU (1) RU2009112397A (enExample)
WO (1) WO2008043087A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010505881A (ja) * 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
EP2131844A1 (en) * 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
PT2247292T (pt) * 2008-03-05 2017-07-17 Merck Patent Gmbh Derivados de piridopirazinonas como estimulantes da secreção de insulina, procedimentos para a sua obtenção e a sua utilização no tratamento da diabetes
KR20100132999A (ko) * 2008-04-04 2010-12-20 길리애드 사이언시즈, 인코포레이티드 스테아로일 ＣｏＡ 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체
EP2274308A1 (en) * 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
WO2009126123A1 (en) * 2008-04-10 2009-10-15 Cv Therapeutics Inc. Bicyclic nitrogen containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JP6254087B2 (ja) 2011-10-15 2017-12-27 ジェネンテック， インコーポレイテッド 癌を治療するためのｓｃｄ１アンタゴニスト
RU2606230C1 (ru) * 2015-10-20 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (Z)-Этил 2-(4-(4-хлорфенил)-2,4-диоксо-3-(3-оксо-3,4-дигидрохиноксалин-2(1Н)-илиден)бутанамидо)-4-метил-5-фенилтиофен-3-карбоксилат, обладающий противодиабетической активностью, и способ его получения
AU2017236879B2 (en) * 2016-03-22 2022-07-21 Balchem Corporation Compositions comprising choline
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
EP3914593A4 (en) 2019-01-24 2022-11-02 Yumanity Therapeutics, Inc. CONNECTIONS AND USES THEREOF
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN118161500A (zh) 2019-11-25 2024-06-11 安进公司 作为δ-5脱饱和酶抑制剂的杂环化合物以及使用方法
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
KR20010042298A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
CA2393896A1 (en) 1999-09-15 2001-03-22 Warner-Lambert Company Pteridinones as kinase inhibitors
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003076416A1 (en) 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
US20040142950A1 (en) 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
CN1829701A (zh) * 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
EP1830869B1 (en) 2004-12-24 2013-05-22 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
JP2010505881A (ja) * 2006-10-05 2010-02-25 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼインヒビターとして使用するための二環式窒素含有複素環式化合物
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
EP2131844A1 (en) 2007-04-09 2009-12-16 CV Therapeutics Inc. PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2274308A1 (en) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
KR20100132999A (ko) 2008-04-04 2010-12-20 길리애드 사이언시즈, 인코포레이티드 스테아로일 ＣｏＡ 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체

Also Published As

Publication number Publication date
AU2007303056A1 (en) 2008-04-10
WO2008043087A2 (en) 2008-04-10
MX2009003658A (es) 2009-04-22
JP2010505881A (ja) 2010-02-25
CA2665476A1 (en) 2008-04-10
US8148376B2 (en) 2012-04-03
RU2009112397A (ru) 2010-10-10
KR20090057416A (ko) 2009-06-05
EP2066665A2 (en) 2009-06-10
BRPI0717502A2 (pt) 2015-06-16
WO2008043087A3 (en) 2008-05-22
IL197828A0 (en) 2009-12-24
US20080139570A1 (en) 2008-06-12
US20100204238A1 (en) 2010-08-12
US7732453B2 (en) 2010-06-08

Similar Documents

Publication Publication Date Title
CN101522676A (zh) 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
US7893066B2 (en) Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2743902C (en) Substituted dioxopiperidinyl phthalimide derivatives
US9045453B2 (en) Substituted dioxopiperidinyl phthalimide derivatives
CN114057771B (zh) 大环化合物及其制备方法和应用
JP7539545B2 (ja) 複素環化合物及びその使用
CN107001378A (zh) 吡咯并嘧啶化合物
US9206179B2 (en) Methods of use comprising deuterated pyrazino[2,1-a]isoquinolines
SG191097A1 (en) 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
CN101610763A (zh) 杂环化合物及其使用方法
WO2019113523A1 (en) Compounds and therapeutic uses thereof
JP2025535816A (ja) 縮合複素環化合物及びその使用
TW200845988A (en) New compounds and their uses 707
KR100191386B1 (ko) 3-(1,2-벤즈이속사졸-3-일)-4-피리딘아민 및 유도체,이를 함유하는 약제학적 조성물 및 이의 제조방법
TW201141861A (en) [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
JP2022504082A (ja) ウイルス感染を処置するための２，６－ジメチル－Ｎ－（（ピリジン－４－イル）メチル）イミダゾ［１，２－ｂ］ピリダジン－８－アミンおよび２，５－ジメチル－Ｎ－［（ピリジン－４－イル）メチル］ピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体
TW200900408A (en) Fused pyridine derivative
WO2012079075A1 (en) Deuterated phthalimide derivatives
JP2011516546A (ja) ステアロイル−ＣｏＡデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物
TW201125860A (en) Prodrugs of [4-[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
CN118176181A (zh) Sarm1调节剂、其制备和用途
CS228531B2 (en) Method for the production of phenylpiperazine derivates
TW541295B (en) A novel substituted alkylteraamine derivative for use as tachykinin antagonist
CN120518616A (zh) 一种喹喔啉类小分子化合物及其应用
HK40070314A (en) Heterocyclic compound, intermediate thereof, preparation method therefor and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100519

Address after: American California

Applicant after: Cv Therapeutics Inc.

Address before: American California

Applicant before: CV Therapeutics Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090902